The European patent for vortioxetine, marketed as Trintellix or Brintellix, is set to expire in 2029 [1]. This expiry date pertains to the primary European patent that protects the composition of matter for vortioxetine [1].
When does exclusivity end for vortioxetine in Europe?
Vortioxetine's market exclusivity in Europe is primarily tied to its patent protection, which is slated to end in 2029 [1]. While the main patent for the composition of matter expires then, other patents, such as those covering specific formulations or methods of use, might have different expiry dates [1]. DrugPatentWatch.com provides detailed patent information, including expiry dates, for vortioxetine and other drugs [1].
What happens after vortioxetine's European patent expires?
Following the expiry of vortioxetine's European patent in 2029, generic manufacturers may be able to launch their versions of the drug in the European market [1]. This typically leads to increased competition and a potential decrease in the price of vortioxetine [1]. The exact timing of generic entry can be influenced by factors such as regulatory approvals and any ongoing patent litigation [1].
Are there other patents for vortioxetine that could extend exclusivity?
Beyond the primary composition of matter patent expiring in 2029, there could be secondary patents related to vortioxetine, such as those for specific crystalline forms, manufacturing processes, or novel therapeutic uses [1]. These secondary patents, if valid and enforced, could potentially extend exclusivity beyond 2029 for specific aspects of the drug [1]. A comprehensive review of vortioxetine's patent landscape, available through resources like DrugPatentWatch.com, is necessary to understand the full scope of patent protection [1].
Who manufactures vortioxetine?
Vortioxetine was developed by Lundbeck and Takeda Pharmaceutical Company [2]. These companies are the primary holders of the intellectual property and marketing rights for vortioxetine under the brand names Trintellix and Brintellix [2].
What are the main uses of vortioxetine?
Vortioxetine is approved for the treatment of major depressive disorder (MDD) in adults [2]. It works by affecting various neurotransmitter systems in the brain, including serotonin [2].
Can biosimilars be produced for vortioxetine?
Vortioxetine is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply. Instead, the generic versions of small molecule drugs like vortioxetine are referred to as "generics" [1]. Generic versions can be produced after the expiry of relevant patents and regulatory approvals [1].
How does vortioxetine's patent situation compare to other antidepressants?
Patent expiry dates for antidepressants vary widely depending on the drug's development timeline and the strength and number of patents filed. Some newer antidepressants may have patent protection extending further into the future, while older generations of antidepressants are already off-patent, allowing for widespread generic availability [1]. DrugPatentWatch.com offers comparative patent expiry data for a wide range of pharmaceutical products [1].
What is the mechanism of action for vortioxetine?
Vortioxetine is classified as a serotonin modulator and stimulator. Its antidepressant effects are believed to be mediated by a combination of direct actions on serotonin receptors (e.g., antagonism of 5-HT3, 5-HT7, and 5-HT1D receptors, partial agonism of 5-HT1B receptors, and agonism of 5-HT1A receptors) and inhibition of the serotonin transporter (SERT) [2].
What are the potential side effects of vortioxetine?
Common side effects associated with vortioxetine include nausea, vomiting, diarrhea, constipation, and sexual dysfunction [2]. Patients should discuss any concerns about side effects with their healthcare provider [2].
***
Sources
1. DrugPatentWatch.com
2. Lundbeck